Search results

Reading this press release, and listening to the conference call, it seems as the company believes this will be a successful trial, potentially leading to a new type of therapy or even a cure.

From the midpoint announcement: "RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III Study with RHB-104 for Crohn's Disease TEL-AVIV, Israel and RALEIGH, N.C., July 31, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL)...